Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Kosiborod M, Berwanger O, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Javaheri A, Ambery P, Gasparyan SB, Buenconsejo J, Sjöström CD, Langkilde AM, Oscarsson J, Esterline R. Kosiborod M, et al. Among authors: ambery p. Diabetes Obes Metab. 2021 Apr;23(4):886-896. doi: 10.1111/dom.14296. Epub 2021 Jan 19. Diabetes Obes Metab. 2021. PMID: 33319454 Free PMC article.
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.
Asano M, Sekikawa A, Kim H, Gasser RA Jr, Robertson D, Petrone M, Jermutus L, Ambery P. Asano M, et al. Among authors: ambery p. Diabetes Obes Metab. 2021 Aug;23(8):1859-1867. doi: 10.1111/dom.14412. Epub 2021 May 19. Diabetes Obes Metab. 2021. PMID: 33908687 Clinical Trial.
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.
Parker VER, Hoang T, Schlichthaar H, Gibb FW, Wenzel B, Posch MG, Rose L, Chang YT, Petrone M, Hansen L, Ambery P, Jermutus L, Heerspink HJL, McCrimmon RJ. Parker VER, et al. Among authors: ambery p. Diabetes Obes Metab. 2022 Jul;24(7):1360-1369. doi: 10.1111/dom.14712. Epub 2022 Apr 25. Diabetes Obes Metab. 2022. PMID: 35403793 Free PMC article. Clinical Trial.
Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
Golubic R, Kennet J, Parker V, Robertson D, Luo D, Hansen L, Jermutus L, Ambery P, Ryaboshapkina M, Surakala M, Laker RC, Venables M, Koulman A, Park A, Evans M. Golubic R, et al. Among authors: ambery p. Diabetes Obes Metab. 2024 Jul;26(7):2634-2644. doi: 10.1111/dom.15579. Epub 2024 Apr 1. Diabetes Obes Metab. 2024. PMID: 38562018 Clinical Trial.
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial.
Ambery P, Zajac G, Almquist J, Prothon S, Astbury C, Brown MN, Nemes S, Nsabimana J, Edman K, Öberg L, Lepistö M, Edenro G, Dillmann I, Mitra S, Belfield G, Keen C, Heise T. Ambery P, et al. Br J Clin Pharmacol. 2024 May 1. doi: 10.1111/bcp.16082. Online ahead of print. Br J Clin Pharmacol. 2024. PMID: 38690606
54 results